Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio
MWN-AI** Summary
Hologic, Inc. (Nasdaq: HOLX) recently announced that its Aptima® HPV Assay has received FDA approval for clinician-collected HPV primary screening, marking a significant addition to the company’s cervical health portfolio. This assay is notable for being the only FDA-approved mRNA-based test specifically designed to identify HPV infections that pose a high risk for developing cervical cancer.
Cervical cancer remains a serious health issue in the U.S., with estimates of around 13,490 new cases and approximately 4,200 fatalities expected in 2026. The approval of the Aptima HPV Assay underscores Hologic’s dedication to improving women’s health by offering diversified screening options that enhance clinical flexibility for healthcare providers. By expanding their testing capabilities, which already include Pap + HPV co-testing and Pap testing, Hologic aims to provide comprehensive solutions tailored to various patient needs based on factors such as age and risk.
Jennifer Schneiders, President of Diagnostic Solutions at Hologic, highlighted that this approval follows one of the largest real-world studies on HPV screening involving over 650,000 women. The study demonstrated that the sensitivity of the Aptima HPV Assay for detecting high-grade cervical lesions is clinically comparable to traditional DNA-based tests.
Hologic's innovative product range supports both cytology and molecular workflows, including the Genius® Digital Diagnostics System, which utilizes AI for detecting precancerous lesions. This initiative not only aligns with Hologic's long-standing commitment to advancing cervical cancer detection and prevention but also enhances the ability of healthcare providers to deliver personalized care. For more information on Hologic’s cervical health solutions, visit Hologic.com.
MWN-AI** Analysis
Hologic, Inc. (NASDAQ: HOLX) has recently secured FDA approval for its Aptima® HPV Assay as a primary screening tool for cervical cancer, a significant enhancement to its cervical health portfolio. This approval positions Hologic favorably in the women’s health sector, particularly as the company continues to innovate in cervical cancer screening methods.
The Aptima HPV Assay is noteworthy as the only FDA-approved mRNA-based test that focuses on detecting high-risk HPV strains linked to cervical cancer. With cervical cancer incidence projected to affect nearly 13,490 women in 2026, alongside several thousand deaths, the introduction of effective screening methods represents a crucial public health advance. Hologic's expansion of screening options—including co-testing (Pap + HPV), Pap testing, and now HPV primary testing—broadens accessibility and provides healthcare providers with adaptable approaches tailored to individual patient needs.
Statistically, cervical cancer screening with co-testing boasts impressive detection rates, capturing up to 95% of cervical cancers. The addition of the Aptima HPV Assay offers comparable sensitivity, ensuring that patients still receive high-quality screening options based on age and risk factors. This flexibility could enhance market penetration, as both clinicians and patients may prefer personalized approaches.
Investors should view Hologic’s proactive regulatory strategy and expanding product lines positively. The strong backing of real-world evidence through a comprehensive study involving over 650,000 women underscores the validity and reliability of the Aptima HPV Assay, suggesting it can achieve commercial success.
As Hologic continues to innovate, coupled with positive systemic health outcomes, its market position may strengthen. Investors might consider Hologic's shares as a growth opportunity, particularly in light of the increasing emphasis on women’s health and cancer prevention technologies. However, ongoing monitoring of market response and product adoption will be essential to gauge long-term growth prospects.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Expanded FDA approval across multiple cervical cancer screening modalities supports clinical flexibility and provider choice
Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima ® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus (HPV) test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126336815/en/
Screening for cervical cancer is critically important to women’s health. In the United States, it is estimated that in 2026, approximately 13,490 new cases of invasive cervical cancer will be diagnosed, and about 4,200 women will die from the disease. 1 However, many of these deaths are preventable with regular screening and appropriate follow-up on abnormal results. Timely follow-up is essential for early detection and treatment to reduce cervical cancer cases and deaths. 1
“Hologic has been at the forefront of cervical cancer screening for decades, and the additional indication of the Aptima HPV Assay reflects our ongoing commitment to advancing women’s health through innovative, evidence-based solutions,” said Jennifer Schneiders, Ph.D., President of Diagnostic Solutions at Hologic. “Our commitment to providing comprehensive cervical health solutions that meet provider and patient needs is unwavering, and by offering providers more choice and flexibility, we can help them deliver the most personalized care for each patient.”
The additional indication for the Aptima HPV Assay expands Hologic’s offerings to now include Pap + HPV (co-testing), Pap testing, and HPV primary testing — three major FDA-approved and guideline-recommended methods for cervical cancer screening. This additional approval for the Aptima HPV Assay follows the clearance of the Genius ® Digital Diagnostics System with the Genius ® Cervical AI Algorithm, which leverages advanced digital imaging and artificial intelligence to help detect cytologic abnormalities and precancerous lesions.
The approval comes following the completion of one of the largest real-world evidence HPV screening studies, involving over 650,000 women across multiple U.S. health systems that reflect diverse, real-life patient populations and clinical settings. This innovative study compared the Aptima HPV Assay to an FDA-approved DNA-based HPV test for primary screening and found that the sensitivity of the Aptima HPV Assay is clinically comparable to the comparator test. The Aptima HPV Assay is effective for use in primary screening for the detection of CIN2+ and CIN3+.
While co-testing remains the most comprehensive screening modality — with more than 90% of providers reporting strong confidence for women ages 30 to 65, and data showing that co-testing (Pap + HPV) detected up to 95% of cervical cancers — Hologic's range of testing options gives providers greater flexibility in selecting an approach based on a patient’s age, access and risk factors. 2-5
About Hologic’s Cervical Health Solutions
Hologic offers a broad portfolio for cervical cancer screening, supporting both cytology and molecular workflows from sample collection to results. The portfolio includes innovations such as the ThinPrep ® Pap Test, the first liquid-based cytology test, the Aptima HPV Assay, the first and only approved mRNA-based HPV tests, and the Genius Digital Diagnostics System, the first and only FDA-cleared digital cytology system. These technologies are designed to support clinicians and laboratory professionals in the detection and prevention of cervical cancer, all backed by Hologic’s support and partnership. To learn more, please visit Hologic.com .
About Hologic, Inc.
Hologic, Inc. is a global leader in women’s health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn , Facebook , X , Instagram and YouTube .
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s and its subsidiaries’ products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Hologic, Aptima, ThinPrep, Genius and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. All other trademarks are the property of their respective owners.
References: 1. American Cancer Society. Cancer Statistics Center. Accessed January 2026. https://cancerstatisticscenter.cancer.org/types/cervix . 2. Austin et al. Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting. Am J Clin Patho 2018; 150:385-392 1. 3. Blatt AJ, et al. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123(5):282-288. doi:10.1002/cncy.21544. 4. Kaufman H, et al. Contributions of Liquid-Based (Papanicolaou) Cytology and Human Papillomavirus Testing in Cotesting for Detection of Cervical Cancer and Precancer in the United States. Am J Clin Pathol. 2020:XX:0-0 DOI: 10.1093/AJCP/AQAA074 (Study included ThinPrep Pap test, ThinPrep imaging, SurePath Pap test, SurePath imaging, Aptima HPV and Hybrid Capture 2). 5. Kruse G, et al. Provider beliefs in effectiveness and recommendations for primary HPV testing in 3 health-care systems. JNCI Cancer Spectrum. 2023;7(1).
SOURCE: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260126336815/en/
Media Contact:
Bridget Perry
Senior Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com
Investor Contact:
Michael Watts
Corporate Vice President, Investor Relations
(+1) 858.410.8514
michael.watts@hologic.com
FAQ**
How does the FDA approval of the Aptima HPV Assay enhance Hologic Inc. (HOLX)'s competitive position in the cervical cancer screening market compared to other major players?
What are the expected financial implications and potential revenue growth for Hologic Inc. (HOLX) following the expansion of its offerings for cervical cancer screening with the Aptima HPV Assay?
How does the real-world evidence study supporting the Aptima HPV Assay compare to existing technologies in terms of sensitivity and effectiveness for early cancer detection, and what impact could this have on Hologic Inc. (HOLX)'s market share?
In light of the new FDA approval, what strategies will Hologic Inc. (HOLX) implement to educate healthcare providers about the benefits of its expanded cervical cancer screening options and encourage adoption?
**MWN-AI FAQ is based on asking OpenAI questions about Hologic Inc. (NASDAQ: HOLX).
NASDAQ: HOLX
HOLX Trading
0.03% G/L:
$75.665 Last:
1,509,096 Volume:
$75.50 Open:
